Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Chimerix Inc
CXFCurrent price
0.89 EUR
-0.088 EUR (-8.88%)
Last closed
0.99 USD
Company
www.chimerix.com
ISIN
US16934W1062
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
88 742 216 USD
Yield for 12 month
-2.06 %
1Y
3Y
5Y
10Y
15Y
CXF
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina. Address: 2505 Meridian Parkway, Durham, NC, United States, 27713
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7 USDP/E ratio
–Dividend Yield
–Current Year
+324 000 USD
Last Year
+33 824 000 USD
Current Quarter
+26 000 USD
Last Quarter
+129 000 USD
Current Year
+323 000 USD
Last Year
+33 377 000 USD
Current Quarter
+26 000 USD
Last Quarter
+105 000 USD
Key Figures CXF
1 year
3 years
5 years
10 years
EBITDA
-94 629 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-28.22 %
PEG Ratio
–
Return On Equity TTM
-44.62 %
Wall Street Target Price
7 USD
Revenue TTM
144 000 USD
Book Value
2.17 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
396.2 %
Dividend Yield
–
Gross Profit TTM
-36 486 000 USD
Earnings per share
-0.96 USD
Diluted Eps TTM
-0.96 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CXF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CXF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation CXF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
1.2136
Enterprise Value Revenue
3.5749
Price Sales TTM
616.2654
Enterprise Value EBITDA
1.0307
Price Book MRQ
0.5646
Financials CXF
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CXF
For 52 weeks
0.75 USD
1.3 USD
50 Day MA
0.9 USD
Shares Short Prior Month
1 797 530
200 Day MA
0.95 USD
Short Ratio
11.28
Shares Short
1 737 729
Short Percent
2.05 %
BeatStart